Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP) (PADIS TVP)

11 januari 2017 bijgewerkt door: University Hospital, Brest

Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Proximal Deep Vein Thrombosis: a Multicentre Double-Blind Randomized Controlled Trial. "PADIS-TVP" Study.

In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of warfarin therapy is associated with a lower cumulative risk of recurrent VTE and major bleeding in comparison with that on 18 months of placebo. The secondary objectives are: (1) to determine the risk of recurrent VTE after 6 months of warfarin therapy and the presence or the absence of residual lung scan perfusion defect and the persistence or not of elevated D-dimer test; and (2), to determine the impact of extended duration of anticoagulation on the risk of VTE after stopping anticoagulant therapy on a follow-up of 2 years.

Studie Overzicht

Gedetailleerde beschrijving

Rational: After 3 or 6 months of oral anticoagulation for an episode of acute venous thromboembolism (VTE), the risk of recurrent VTE is high (10 to 15% per year) in comparison with a low risk of recurrence if VTE was provoked by a major transient risk factor such as recent surgery (3% per year) independently of the initial presentation (deep vein thrombosis or pulmonary embolism). After a first episode of idiopathic VTE, 3 months of anticoagulation is associated with a very high risk of recurrence (27% per year); however, the benefit-risk of extended duration of anticoagulation (1 to 2 years) remains uncertain, mainly in relation with an increased risk of anticoagulant related bleeding. Therefore, the last ACCP conference group recommended 6 months of oral anticoagulant therapy after a first episode of idiopathic VTE. However, this recommendation is likely to be inadequate for at least two main reasons: (1) no studies compared 2 years to 6 months of anticoagulation after idiopathic VTE; and (2), if the frequency of recurrent VTE is similar after deep vein thrombosis and pulmonary embolism, however, the case fatality rate of recurrent VTE is higher after pulmonary embolism (12%) than after deep vein thrombosis (5%).

Objective : the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of warfarin therapy is associated with a lower cumulative risk of recurrent VTE and major bleeding in comparison with that on 18 months of placebo. The secondary objectives are: (1) to determine the risk of recurrent VTE after 6 months of warfarin therapy and the presence or the absence of residual lung scan perfusion defect and the persistence or not of elevated D-dimer test; and (2), to determine the impact of extended duration of anticoagulation on the risk of VTE after stopping anticoagulant therapy on a follow-up of 2 years.

Method : French multicenter double blind randomized controlled trial. Inclusion and exclusion criteria and deep vein thrombosis diagnostic criteria have been defined. After completing 6 months of oral anticoagulation, a leg ultrasound and D-dimer testing are performed; the investigators and the patients will be unaware of the results of these tests. Then, patients are randomized to receive 18 months of warfarin therapy or 18 months of placebo (the dose of placebo will be adapted according to false computer generated INR). The investigators, the radiologists and the patients are blinded of the treatment allocation. The project has been accepted by national ethical committee and written consent will be obtained from all included patients.

Required number of patients: the expected cumulative frequency of recurrent VTE and major bleeding over 18 months is 4.5% while on warfarin therapy and 16% while on placebo. For a α risk of 5% (to falsely conclude to a true difference) and a β risk of 10% (to falsely conclude to an absence of difference), 178 patients per group should be included. As 5% of patients are expected to be loss, a total of 374 patients is required.

Feasibility: about 50 patients per year are hospitalized in our department of medicine in Brest for an acute episode of idiopathic deep vein thrombosis. Four additional centers will participate to the study and have a similar recruitment: HEGP (Pr Meyer, Dr Sanchez), CHU Antoine Béclère (Dr Parent, Pr Simmoneau), CHU Saint Etienne (Pr Mismetti, Pr Décousus), CHU Grenoble (Pr Pison, Pr Carpentier). The study will be coordinated by the Clinical Center of Investigation of Brest Hospital; "true" and "false" INR will be generated by the clinic of anticoagulant of "Ile de France" (Dr Cambus).

Clinical implications: the first consequence of the study is to demonstrate that 6 months of warfarin therapy is inadequate and should be continued for at least 18 additional months after a first episode of idiopathic proximal deep vein thrombosis. This study has also the potential to confirm or not the contribution of ultrasound of lower limb and D-dimer testing to appreciate the risk of recurrent VTE after stopping anticoagulant therapy. Lastly, the medical economical impact of such therapeutic management will be evaluated.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

104

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Brest, Frankrijk, 29609
        • CHRU de Brest
      • Grenoble, Frankrijk, 38043
        • CHU de GRENOBLE
      • Lannion, Frankrijk, 22303
        • Centre Hospitalier Pierre Le Damany
      • Lorient, Frankrijk, 56322
        • Centre Hospitalier de Bretagne Sud
      • Nantes, Frankrijk, 44093
        • Centre Hospitalier Universitaire de Nantes
      • Paris, Frankrijk, 75015
        • Hôpital Europeén Georges Pompidou
      • Paris, Frankrijk, 75004
        • AP HP Hôpital Hôtel Dieu
      • Poitiers, Frankrijk, 86021
        • CHU De Poitiers
      • Quimper, Frankrijk, 29000
        • Centre Hospitalier de Cornouaille
      • Rennes, Frankrijk, 35023
        • CHU de Rennes
      • Saint Brieuc, Frankrijk, 22023
        • Centre Hospitalier de Saint Brieuc
      • Toulouse, Frankrijk, 31000
        • Hôpital de Rangueil
      • Tours, Frankrijk, 37000
        • CHU de Tours
      • Vernon, Frankrijk, 27200
        • Centre Hospitalier Intercommunal

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients with a first episode of idiopathic proximal deep vein thrombosis who have been treated during 6 months (Plus or minus 15 days) using Vitamin K antagonist with a INR between 2 and 3.

Exclusion Criteria:

  • Age > 18
  • warfarin hypersensibility
  • unwilling or unable to give writting informed consent
  • distal deep vein thrombosis or pulmonary embolism
  • Proximal deep vein thrombosis which was provoked by a reversible major risk factor
  • major thrombophilia (protein C, S or antithrombin deficiency, antiphospholipids antibodies, homozygous factor V Leiden)
  • previous documented episode of proximale deep vein thrombosis or pulmonary embolism
  • other indication for anticoagulant therapy (e.g.:atrial fibrillation, mechanic valve)
  • patient on antithrombotic agent in whom antithrombotic agent should be started again after stopping anticoagulation
  • pregnancy
  • women without contraception
  • planned major surgery in the next 18 months
  • ongoing cancer or cured cancer in less than 2 years
  • serious bleeding risk (e.g.: gastric ulcer)
  • platelet count less than 100 Giga/l
  • Life expectancy less than 18 months

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Actieve vergelijker: 1
18 maanden actieve warfarinetherapie
18 months of warfarin therapy
Placebo-vergelijker: 2
18 maanden placebo van warfarine
18 months of placebo of warfarin therapy

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
symptomatic recurrent venous thromboembolism and serious bleedings
Tijdsspanne: validated standardized objective tests
validated standardized objective tests

Secundaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
mortality due to another cause than recurrent venous thromboembolism or serious bleeding
Tijdsspanne: medical report and death certificates
medical report and death certificates

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Francis Couturaud, MD, PhD, EA3878, IFR148

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 juli 2007

Primaire voltooiing (Werkelijk)

1 januari 2017

Studie voltooiing (Werkelijk)

1 januari 2017

Studieregistratiedata

Eerst ingediend

22 augustus 2008

Eerst ingediend dat voldeed aan de QC-criteria

22 augustus 2008

Eerst geplaatst (Schatting)

25 augustus 2008

Updates van studierecords

Laatste update geplaatst (Schatting)

12 januari 2017

Laatste update ingediend die voldeed aan QC-criteria

11 januari 2017

Laatst geverifieerd

1 januari 2017

Meer informatie

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren